Article info
Ethics
Uncomfortable implications: placebo equivalence in drug management of a functional illness
- Professor H M Evans, Centre for Arts and Humanities in Health and Medicine, Durham University, School House, St Hild's Lane, Durham DH1 1SZ, UK; h.m.evans{at}durham.ac.uk
Citation
Uncomfortable implications: placebo equivalence in drug management of a functional illness
Publication history
- Received October 26, 2006
- Revised January 15, 2007
- Accepted January 31, 2007
- First published October 30, 2007.
Online issue publication
October 30, 2007
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2007 BMJ Publishing Group & Institute of Medical Ethics
Other content recommended for you
- Irritable bowel syndrome: new and emerging treatments
- Guidelines on the irritable bowel syndrome: mechanisms and practical management
- Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial
- British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
- The ethics of the placebo in clinical practice revisited
- Best management of irritable bowel syndrome
- Irritable bowel syndrome
- Management of irritable bowel syndrome
- Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial
- Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial